Karyopharm Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KPTI research report →
Companywww.karyopharm.com
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
- CEO
- Richard A. Paulson
- IPO
- 2013
- Employees
- 279
- HQ
- Newton, MA, US
Price Chart
Valuation
- Market Cap
- $68.13M
- P/E
- -0.90
- P/S
- 0.45
- P/B
- -0.66
- EV/EBITDA
- -1.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.03%
- Op Margin
- -55.73%
- Net Margin
- -129.02%
- ROE
- 73.11%
- ROIC
- -177.79%
Growth & Income
- Revenue
- $146.07M · 0.57%
- Net Income
- $-196,039,000 · -156.52%
- EPS
- $-17.93 · -90.54%
- Op Income
- $-90,707,000
- FCF YoY
- 40.95%
Performance & Tape
- 52W High
- $10.99
- 52W Low
- $3.65
- 50D MA
- $7.89
- 200D MA
- $6.92
- Beta
- 0.81
- Avg Volume
- 943.84K
Get TickerSpark's AI analysis on KPTI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Poulton Stuart | other | 896 |
| May 14, 26 | Poulton Stuart | sell | 403 |
| May 13, 26 | Rangwala Reshma | other | 947 |
| May 14, 26 | Rangwala Reshma | sell | 408 |
| May 13, 26 | Cheng Sohanya Roshan | other | 947 |
| May 14, 26 | Cheng Sohanya Roshan | sell | 324 |
| May 13, 26 | Abate Kristin | other | 121 |
| May 14, 26 | Abate Kristin | sell | 53 |
| May 13, 26 | Paulson Richard A. | other | 4,920 |
| May 14, 26 | Paulson Richard A. | sell | 2,203 |
Our KPTI Coverage
We haven't published any research on KPTI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KPTI Report →